These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 23726226)

  • 1. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.
    Yu B; Mao Y; Yuan Y; Yue C; Wang X; Mo X; Jarjoura D; Paulaitis ME; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Biomaterials; 2013 Aug; 34(26):6185-93. PubMed ID: 23726226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
    Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
    Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.
    Robak T
    Expert Rev Hematol; 2014 Dec; 7(6):841-57. PubMed ID: 25249370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.
    Smolewski P; Robak P; Cebula-Obrzut B; Misiewicz M; Mędra A; Majchrzak A; Witkowska M; Stromatt S; Robak T
    Eur J Cancer; 2014 Oct; 50(15):2677-84. PubMed ID: 25154027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.
    Robak T
    Future Oncol; 2013 Jan; 9(1):69-91. PubMed ID: 23252565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.
    Beckwith KA; Frissora FW; Stefanovski MR; Towns WH; Cheney C; Mo X; Deckert J; Croce CM; Flynn JM; Andritsos LA; Jones JA; Maddocks KJ; Lozanski G; Byrd JC; Muthusamy N
    Leukemia; 2014 Jul; 28(7):1501-10. PubMed ID: 24445867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
    Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
    Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.
    Mao Y; Wang J; Zhao Y; Wu Y; Kwak KJ; Chen CS; Byrd JC; Lee RJ; Phelps MA; Lee LJ; Muthusamy N
    Nanomedicine; 2014 Feb; 10(2):393-400. PubMed ID: 23969101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DuoHexaBody-CD37
    Oostindie SC; van der Horst HJ; Kil LP; Strumane K; Overdijk MB; van den Brink EN; van den Brakel JHN; Rademaker HJ; van Kessel B; van den Noort J; Chamuleau MED; Mutis T; Lindorfer MA; Taylor RP; Schuurman J; Parren PWHI; Beurskens FJ; Breij ECW
    Blood Cancer J; 2020 Apr; 10(3):30. PubMed ID: 32341336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies.
    Bobrowicz M; Kubacz M; Slusarczyk A; Winiarska M
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD37 antibodies for chronic lymphocytic leukemia.
    Robak T; Robak P
    Expert Opin Biol Ther; 2014 May; 14(5):651-61. PubMed ID: 24555705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
    Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR
    Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action of novel CD37 antibodies on chronic lymphocytic leukemia cells.
    Krause G; Patz M; Isaeva P; Wigger M; Baki I; Vondey V; Kerwien S; Kuckertz M; Brinker R; Claasen J; Frenzel LP; Wendtner CM; Heider KH; Hallek M
    Leukemia; 2012 Mar; 26(3):546-9. PubMed ID: 21886169
    [No Abstract]   [Full Text] [Related]  

  • 14. Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
    Rafiq S; Siadak A; Butchar JP; Cheney C; Lozanski G; Jacob NK; Lapalombella R; McGourty J; Moledor M; Lowe R; Setter B; Jones J; Flynn JM; Andritsos L; Devine S; Mo X; Jarjoura D; Tridandapani S; Algate P; Byrd JC; Muthusamy N
    MAbs; 2013; 5(5):723-35. PubMed ID: 23883821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.
    Zhao X; Lapalombella R; Joshi T; Cheney C; Gowda A; Hayden-Ledbetter MS; Baum PR; Lin TS; Jarjoura D; Lehman A; Kussewitt D; Lee RJ; Caligiuri MA; Tridandapani S; Muthusamy N; Byrd JC
    Blood; 2007 Oct; 110(7):2569-77. PubMed ID: 17440052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
    Lapalombella R; Yu B; Triantafillou G; Liu Q; Butchar JP; Lozanski G; Ramanunni A; Smith LL; Blum W; Andritsos L; Wang DS; Lehman A; Chen CS; Johnson AJ; Marcucci G; Lee RJ; Lee LJ; Tridandapani S; Muthusamy N; Byrd JC
    Blood; 2008 Dec; 112(13):5180-9. PubMed ID: 18772452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the treatment outcome of patients with chronic lymphocytic leukemia through targeted antibody therapy.
    Stephens DM; Byrd JC
    Hematol Oncol Clin North Am; 2013 Apr; 27(2):303-27. PubMed ID: 23561475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
    Mani R; Mao Y; Frissora FW; Chiang CL; Wang J; Zhao Y; Wu Y; Yu B; Yan R; Mo X; Yu L; Flynn J; Jones J; Andritsos L; Baskar S; Rader C; Phelps MA; Chen CS; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
    Leukemia; 2015 Feb; 29(2):346-55. PubMed ID: 24947019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
    Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism.
    Pedersen IM; Buhl AM; Klausen P; Geisler CH; Jurlander J
    Blood; 2002 Feb; 99(4):1314-9. PubMed ID: 11830481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.